Inter- and intraobserver agreement of the quantitative assessment of $[^{99m}\text{Tc}]$-labelled anti-programmed death-ligand 1 (PD-L1) SPECT/CT in non-small cell lung cancer

Daniel Johnathan Hughes$^{1,2}$, Gitasha Chand$^{1,3,4}$, Vicky Goh$^{1,5}$ and Gary J. R. Cook$^{1,2}$

Abstract

Purpose: Checkpoint inhibition therapy using monoclonal antibodies against programmed cell death protein 1 (PD-1) or its ligand (PD-L1) is now standard management of non-small cell lung cancer (NSCLC). PD-L1 expression is a validated and approved prognostic and predictive biomarker for anti-PD-1/PD-L1 therapy. Technetium-99 m $[^{99m}\text{Tc}]$-labelled anti-PD-L1 single-domain antibody (NM-01) SPECT/CT quantification correlates with PD-L1 expression in NSCLC, presenting an opportunity for non-invasive assessment. The aim of this study was to determine the inter- and intraobserver agreement of the quantitative assessment of $[^{99m}\text{Tc}]$NM-01 SPECT/CT in NSCLC.

Methods: $[^{99m}\text{Tc}]$NM-01 SPECT/CT studies of 21 consecutive NSCLC participants imaged for the evaluation of PD-L1 expression were analysed. Three independent observers measured maximum counts in a tumour region of interest (ROI$_{\text{max}}$) of primary lung, metastatic lesions and normal tissue references of both 1 and 2 h post-injection ($n$ = 42) anonymised studies using a manual technique. Intraclass correlation coefficients (ICC) were calculated, and Bland–Altman plot analysis was performed to determine inter- and intraobserver agreement.

Results: Intraclass correlation of primary lung tumour-to-blood pool (T:BP; ICC 0.83, 95% CI 0.73–0.90) and lymph node metastasis-to-blood pool (LN:BP; ICC 0.97, 0.81–0.92) measures of $[^{99m}\text{Tc}]$NM-01 uptake was good to excellent between observers. Freehand ROI$_{\text{max}}$ of T (ICC 0.94), LN (ICC 0.97), liver (ICC 0.97) and BP (ICC 0.90) reference tissues also demonstrated excellent interobserver agreement. ROI$_{\text{max}}$ scoring of healthy lung demonstrated moderate to excellent interobserver agreement (ICC 0.84) and improved when measured consistently at the level of the aortic arch (ICC 0.89). Manual ROI$_{\text{max}}$ scoring of T, LN, T:BP and LN:BP using $[^{99m}\text{Tc}]$NM-01 SPECT/CT following a 42-day interval was consistent with excellent intraobserver agreement (ICC range 0.95–0.97).

Conclusion: Good to excellent inter- and intraobserver agreement of the quantitative assessment of $[^{99m}\text{Tc}]$NM-01 SPECT/CT in NSCLC was demonstrated in this study, including T:BP which has been shown to correlate with PD-L1 expression. $[^{99m}\text{Tc}]$NM-01 SPECT/CT has the potential to reliably and non-invasively assess PD-L1 expression.

Clinical trial registration: ClinicalTrials.gov identifier no. NCT02978196. Registered 30th November 2016.

*Correspondence: gary.cook@kcl.ac.uk
$^1$Department of Cancer Imaging, School of Biomedical Engineering and Imaging Sciences, King’s College London, 4th Floor, Lambeth Wing, St Thomas’ Hospital, Westminster Bridge Road, London SE1 7EH, UK

Full list of author information is available at the end of the article.
Keywords: Technetium, SPECT, Non-small cell lung cancer, Immunotherapy, PD-L1, Single-domain antibody (sdAb)

Background
Lung cancer is the most commonly diagnosed cancer globally and a leading cause of mortality with over 1.7 million deaths in 2018 alone [1]. Therapeutic molecular-targeting agents have resulted in significant improvements in progression-free and overall survival in advanced non-small cell lung cancer (NSCLC); however, targetable genetic aberrations represent only a small proportion of cases [2]. The introduction of monoclonal antibodies targeting immune checkpoint molecules including programmed cell death protein 1 (PD-1) and its ligand (PD-L1) has revolutionised the treatment paradigm of NSCLC. An important mechanism of immune escape involves the upregulation of co-inhibitory molecule PD-L1 by tumour cells, which on interaction with PD-1, expressed by effector T cells, lead to their dysfunction. Anti-PD-1/PD-L1 therapy improves median overall survival in advanced NSCLC in both first- and second-line settings compared to standard cytotoxic chemotherapy, with durable responses seen in around 20% [3–6].

PD-L1 expression determined by immunohistochemistry (IHC) is a widely validated biomarker correlating with anti-PD-1/PD-L1 therapeutic response and survival [4–7]. Despite this correlation, up to 10% of patients deemed ‘non-expressers’ by IHC respond to anti-PD-1/PD-L1 therapy [4]. Heterogeneity of PD-L1 expression both within and between tumours is well reported, as are changes over time particularly following exposure to anti-cancer therapies [8, 9]. Considering that multiple or serial biopsies are impractical and associated with increased risk to individual patients, this temporospatial heterogeneity presents a particular challenge as needle biopsy only samples a small area of the tumour. Additionally, there are multiple IHC assays available which may assess PD-L1 expression on tumour or infiltrative immune cells alone or in combination [10]. Considering a potential for false negative results with IHC and the limitations described, non-invasive imaging techniques present a potential solution and opportunity to improve the predictive value of PD-L1 assessment.

NM-01 is a camelid single-domain antibody against PD-L1 that when radiolabelled with technetium-99 m ([99mTc]) can be detected by single-photon emission computed tomography (SPECT). Recently, we have reported results from a first-in-human study of [99mTc]NM-01 that demonstrated both safety and acceptable dosimetry in the first 16 recruited participants with NSCLC [11]. SPECT/computed tomography (CT) scans were obtained 1 and 2 h following [99mTc]NM-01 injection with primary tumour-to-blood pool ratio (T:BP) assessment correlating with PD-L1 expression determined by IHC. Additionally, uptake was demonstrated in nodal and bone metastases with heterogeneity of expression in 30% of cases. This novel single-domain antibody presents an opportunity for the non-invasive total tumoural assessment of PD-L1 that could help clinicians better stratify patients to receive the most appropriate anti-cancer therapy at the right time in their disease course. Our hypothesis was that quantitative measurement of PD-L1 expression using [99mTc]NM-01 SPECT/CT is consistent and reproducible between and within observers. The aim of this study was to determine the reproducibility of and agreement between experienced and less experienced observers within a cohort of patients with NSCLC.

Method
Participants aged between 18 and 75 years with histologically confirmed, untreated NSCLC and an Eastern Cooperative Oncology Group (ECOG) performance score of 0–2 were eligible to participate and undergo [99mTc]NM-01 SPECT/CT. Exclusion criteria included pregnancy or lactating females, severe infection and inability to provide biopsy sample for assessment of PD-L1. The study was registered with ClinicalTrials.gov identifier no. NCT02978196. Ethics approval was obtained from Shanghai General Hospital Ethics Committee (approval no. 2016KY220), and all enrolled participants provided written informed consent [11].

SPECT/CT protocol
SPECT/CT examinations were performed on a GE Discovery NM670 SPECT/CT scanner (GE Healthcare; NY, USA). Participants were administered an intravenous bolus of [99mTc]NM-01 (3.8–8.4 MBq/kg) equivalent to 100 μg (n = 18; 1.65 ± 0.46 μg/kg; range 1.19–2.11 μg/kg) and (9.1–10.4 MBq/kg) equivalent to 400 μg (n = 3; 5.81 ± 0.25 μg/kg; range 5.56–6.06 μg/kg). Participants were asked to drink 300–500 mL water post-injection and void bladder prior to imaging. Following an uptake time of 60 min, a low-dose CT was performed for anatomical correlation and attenuation correction. SPECT imaging, focusing on primary tumour (thorax) and site(s) of suspected metastases, was performed with the patient supine at 1 and 2 h post-injection at 10 cm/slice/min. Scans were performed as previously described using low-energy high-resolution collimators with a ±10% energy window centred at 140 keV in a 64 × 64 matrix for tomographic images [11]. A 10% energy window centred...
at 120 keV was also used for tomographic image acquisition for scatter correction. SPECT was performed over 360° in 60 frames per rotation with 20-s acquisition per frame. Images were reconstructed using OSEM iterative reconstruction (2 iterations, 10 subsets) at a matrix size of 128 × 128 using scatter correction.

**Image analysis**

Images were reviewed by three independent observers blinded to patient details and each other’s assessments using Hermes GOLD™ (Hermes Medical Solutions; Stockholm, Sweden). The observers included one nuclear medicine physician, one nuclear medicine clinical fellow in training and one oncology clinical fellow PhD student with 30, 3 and 1 years of experience in nuclear medicine image analysis, respectively. Regions of interest including primary tumour and metastatic lesions, including lymph nodes and normal tissue references (lung, liver and blood pool), were identified with CT correlation. Using a freehand manual technique, the maximum count for regions of interest (ROI\(_{\text{max}}\)) was recorded from 1- and 2-h SPECT images (\(n=42\)) for each patient. ROI\(_{\text{max}}\) was chosen as ROI\(_{\text{mean}}\) could be affected by differences in the manual segmentation and is more likely to be affected by the partial volume effect. In addition, the method using ROI\(_{\text{max}}\) was previously shown to correlate with IHC [11]. Freehand ROI\(_{\text{max}}\) was recorded for normal lung in the right upper lobe (or contralateral upper lobe if pathology present) for calculation of tumour-to-lung (T:L) ratio and for blood pool within the aortic arch for calculation of tumour-to-blood pool (T:BP) ratio. To evaluate if rule-based approaches improved consistency of scoring of normal tissue references, ROI\(_{\text{max}}\) was also recorded using a standardised 3-cm-diameter sphere for normal lung at the level of the aortic arch and carina, and the liver at the level of the gastroesophageal junction (GOJ) on axial view. Examples of image analysis are provided in Fig. 1.

To determine intraobserver agreement, the two independent observers with least experience (one nuclear medicine and one oncology clinical fellow) repeated their calculations for all measured regions blind to their initial measurements following a 42-day period.

**Statistical analysis**

Intraclass correlation coefficient (ICC) is a reliability index that represents both the degree of correlation but also the agreement between measurements. A full description of their interpretation and formulae is described in the literature [12]. ICC and their 95% confidence intervals (CIs) were calculated using a two-way random consistent model, to determine interobserver agreement between all three observers. ICC and their 95% CI were calculated using a two-way mixed effects absolute agreement model, to determine intraobserver agreement for two observers. ICC values range from 0 to 1, where the values less than 0.5 indicate poor agreement, 0.5–0.75 moderate, 0.75–0.9 good, and greater than 0.9, i.e. close to 1, represent excellent agreement [12]. As the ICC

---

**Fig. 1** Image analysis using ROI\(_{\text{max}}\) scoring of \(^{99m}\)Tc-NM-01 SPECT/CT of: primary left lower lobe tumour, IHC PD-L1 65% (a), freehand; unaffected lung tissue freehand (b) and using a 3-cm sphere at level of the aortic arch (c); blood pool reference tissue (d); liver reference tissue freehand (e) and using a 3-cm sphere at the axial level of the gastroesophageal junction (f).
obtained is an estimated value of the true ICC, the levels of agreements are defined by their 95% confidence intervals. Bland–Altman plots and their 95% limits of agreement were used to determine the agreement between observers and their repeat measurements for logarithm-transformed T:BP and LN:BP scores. Linear regression of Bland–Altman plots was performed to determine the β coefficient of the mean difference and demonstrate any proportional bias (where \( p < 0.05 \) is significant). Statistical analysis was performed using IBM SPSS Statistics for Windows, version 26.0 (Armonk, NY: IBM Corp.).

Results

Participant characteristics

Participants were recruited to the study between March 2018 and April 2019 (\( n = 21 \)). The median age was 65 years (range 36–75 years); all were of Asian ethnicity. All had a histologically confirmed diagnosis of NSCLC (adenocarcinoma \( n = 10 \), squamous cell carcinoma \( n = 11 \)) with 9 of 21 participants having metastatic disease. A full summary of participant characteristics is provided in Table 1.

Interobserver agreement

There was excellent agreement of manual freehand ROImax scoring between all three observers of primary lung tumour (T; ICC 0.94; 95% CI 0.9–0.97), lymph node metastases (LN; ICC 0.97; 0.95–0.98) and blood pool healthy reference tissue (BP; ICC 0.9; 0.84–0.96) using [99mTc]NM-01 SPECT/CT (Table 2). T:BP (ICC 0.83; 0.73–0.90) and LN:BP (ICC 0.87; 0.81–0.92) ratios, which provide a quantitative measure of [99mTc]NM-01 uptake for primary lung tumour and lymph node metastases on SPECT/CT, respectively, both demonstrated good interobserver agreement. Bland–Altman plot analysis demonstrated interobserver agreement with no proportional bias on linear regression for T:BP scores (Fig. 2). Bland–Altman analysis for LN:BP scores (Fig. 2) did, however, demonstrate proportional bias for observer B compared with both observer A (\( \beta = 0.11, p = 0.047 \)) and observer C (\( \beta = 0.05, p = 0.02 \)). There was acceptable agreement and no proportional bias for LN:BP scores between observers A and C (\( \beta = 0.06, p = 0.448 \)).

Manual ROImax scoring of non-affected lung background reference tissue demonstrated moderate to excellent interobserver agreement (ICC 0.84; 0.75–0.90). The ICC was improved with good to excellent agreement when either rule-based approach was applied, measuring ROImax at the level of the aortic arch (ICC 0.89; 0.82–0.93) or the carina (ICC 0.88; 0.81–0.93). Calculated T:L ratios, when measuring healthy lung ROImax at the level of the aortic arch, were also improved to good to excellent (ICC 0.85; 0.77–0.91) compared to moderate to excellent agreement demonstrated with freehand (ICC 0.79; 0.68–0.88) and carina rule-based (ICC 0.80; 0.69–0.88) approaches.

Excellent interobserver agreement (ICC 0.97; 0.95–0.98) was also demonstrated of freehand ROImax scores for healthy reference tissue liver. Applying a consistent rule-based approach to score the liver at the level of the gastroesophageal junction did not improve agreement further (ICC 0.95; 0.92–0.97).

Using a T:BP score of \( \geq 2.32 \) to represent a PD-L1 of \( \geq 1\% \), the interobserver mean sensitivity was 61% and specificity 73% for this cohort (Table 3). Discrepant cases were reviewed, and a consensus was made between the three observers defining the T:BP as either \(< 0.232 \) (Table 3). Discrepant cases with PD-L1 expression between 1 and 10% on IHC remained discordant, four of which were considered negative PD-L1 by T:BP score of [99mTc]NM-01 SPECT/CT but positive (\( \geq 1\% \)) by IHC.

Intraobserver agreement

Manual ROImax scoring of primary lung tumour, lymph node metastases and blood pool reference tissue using [99mTc]NM-01 SPECT/CT following a 42-day interval was consistent for the two observers analysed (Table 5). The intraobserver ICC for primary lung tumour ROImax scores for observer B (ICC 0.96; 95% CI 0.93–0.98) and observer C (ICC 0.95; 0.91–0.97) demonstrated excellent agreement. Scoring of lymph node metastases also demonstrated excellent agreement (observer B ICC 0.97; observer C ICC 0.97, see Table 5 for 95% CIs). The intraobserver ICC for freehand ROImax scores for reference tissue blood pool (observer B ICC 0.98; observer C ICC 0.97) confirmed excellent agreement. Excellent intraobserver agreement of both T:BP and LN:BP ratios for both observer B (ICC 0.96 and 0.95, respectively) and observer C (ICC 0.95 and 0.95) were also demonstrated. Bland–Altman plot analysis demonstrated intraobserver agreement with no proportional bias on linear regression for both T:BP and LN:BP scores (Fig. 3).

The intraobserver ICC for freehand ROImax scores for healthy lung (observer B ICC 0.87; observer C ICC 0.91) and liver (observer B ICC 0.98; observer C ICC 0.99) demonstrated good to excellent agreement. A trend towards improved intraobserver agreement with rule-based approaches for healthy lung scoring was demonstrated, but no overall difference in the level of agreement was seen. Calculated T:L ratios demonstrated no proportional bias for both T:BP and LN:BP scores (Fig. 3).
### Table 1 Participant demographics

| Patient no. | Age (yrs) | Sex | ECOG score | Tumour histology | TNM staging | Primary tumour size (mm) | Disease site(s) | PD-L1 expression (%) | Administered radioactivity (MBq/kg) |
|-------------|-----------|-----|------------|------------------|-------------|-------------------------|----------------|----------------------|----------------------------------|
| 1           | 49        | M   | 1          | Adenocarcinoma   | T4N3M1      | 37 x 27                 | RUL, multiple mediastinal LNs, renal | –                    | 4.84                             |
| 2           | 75        | M   | 1          | Squamous cell carcinoma | T3N3M1      | 44 x 48                 | LLL, multiple mediastinal LNs and chest wall | 20                   | 6.9                              |
| 3           | 75        | M   | 1          | Squamous cell carcinoma | T2bN3M0     | 55 x 46                 | LLL, localised LNs | 0                    | 7.50                             |
| 4           | 65        | M   | 0          | Adenocarcinoma   | T2bN3M1     | 48 x 42                 | LUL, bilateral lung and bone | 36                   | 9.12                             |
| 5           | 57        | M   | 0          | Squamous cell carcinoma | T2N2M0      | 32 x 35                 | RUL, multiple mediastinal LNs | 55                   | 10.38                            |
| 6           | 65        | M   | 0          | Squamous cell carcinoma | T4N3M0      | 30 x 58                 | RUL, multiple mediastinal LNs | 90                   | 9.63                             |
| 7           | 75        | F   | 0          | Adenocarcinoma   | T4N3M1      | 38 x 28                 | –                   | 4.81                             |
| 8           | 52        | F   | 0          | Squamous cell carcinoma | T2aN0M0    | 33 x 23                 | LUL, – | 0                    | 7.25                             |
| 9           | 36        | F   | 1          | Adenocarcinoma   | T2aN2M1     | 45 x 18                 | LUL, multiple mediastinal LNs and multiple bone | 1                    | 7.59                             |
| 10          | 47        | F   | 0          | Adenocarcinoma   | T3N1M0      | 32 x 35                 | LUL, localised LNs | 50                   | 6.56                             |
| 11          | 51        | M   | 0          | Squamous cell carcinoma | T2aN3M1     | 47 x 35                 | LUL, mediastinal LNs | 2                    | 3.77                             |
| 12          | 72        | M   | 1          | Adenocarcinoma   | T2N3M1      | 71 x 27                 | LUL, multiple mediastinal LNs | –                    | 6.54                             |
| 13          | 55        | M   | 0          | Squamous cell carcinoma | T4N1M1c     | 71 x 78                 | LUL, liver | 85                   | 8.41                             |
| 14          | 69        | M   | 0          | Squamous cell carcinoma | T3N1M0      | 20 x 28                 | LUL, mediastinal LNs | 10                   | 6.59                             |
| 15          | 71        | F   | 1          | Squamous cell carcinoma | T4N1M1a     | 78 x 95                 | LUL, mediastinal and distant LNs | –                    | 6.02                             |
| 16          | 60        | M   | 0          | Adenocarcinoma   | T4N3M1a     | 93 x 75                 | RUL, multiple bilateral mediastinal LNs, chest wall, renal | 2                    | 5.58                             |
| 17          | 70        | M   | 0          | Adenocarcioma   | T3N1M0      | 66 x 44                 | LUL, mediastinal LNs | 65                   | 5.33                             |
| 18          | 41        | F   | 0          | Squamous cell carcinoma | T3N2M1     | 66 x 52                 | RLL, mediastinal LNs, lung | 2                    | 7.14                             |
| 19          | 69        | M   | 1          | Squamous cell carcinoma | T2N2M1     | 35 x 90                 | LLL, mediastinal LNs, bone | –                    | 6.78                             |
| 20          | 58        | M   | 1          | Adenocarcioma   | T2NXM1      | 49 x 35                 | LLL, bilateral mediastinal and distant LNs | 0                    | 5.84                             |
| 21          | 48        | M   | 1          | Adenocarcioma   | T1N3M0      | 40 x 30                 | Right hilar, multiple mediastinal LNs | 0                    | 4.56                             |

ECOG Eastern Cooperative Oncology Group Performance score, – denotes an inconclusive result, LLL left lower lobe, LNs lymph nodes, LUL left upper lobe, RLL right lower lobe, RUL right upper lobe.
Our study demonstrates that the quantitative assessment of $^{99m}$TcNM-01 using SPECT/CT is both reliable and reproducible within and between independent observers. Interobserver agreement was demonstrated for both T:BP (ICC 0.83) and LN:BP (ICC 0.87). In addition, excellent intraobserver agreement was shown (T:BP ICC 0.95–0.96; LN:BP ICC 0.95). This provides further evidence that $^{99m}$TcNM-01 has significant potential and clinical utility, as a diagnostic agent for the measurement of PD-L1. Non-invasive assessment of PD-L1 is an attractive possibility, considering the dynamic nature and heterogeneity of its expression. $^{99m}$TcNM-01 uptake measured by TBP on SPECT/CT has already been shown to correlate with PD-L1 expression measured by ICC (r = 0.66, p = 0.014) [11]. This study, which confirms good to excellent inter- and intraobserver agreement of the quantitative assessment of $^{99m}$TcNM-01 SPECT/CT, supports its potential to provide reliable assessment of PD-L1 expression. It remains unclear whether temporal changes in PD-L1 expression and response assessment using $^{99m}$TcNM-01 SPECT/CT following anti-PD-1/PD-L1 therapy will be demonstrated and of clinical utility. This will be further explored in a phase I clinical trial, PECan [NCT04436406], which will also compare changes in PD-L1 expression and response to parameters on $^{18}$F FDG PET/CT in both NSCLC and malignant melanoma. This study is the first to assess the agreement of SPECT/CT in measuring PD-L1 expression in cancer. Several other radionuclides are currently being developed specifically for imaging the PD-1/PD-L1 axis. $^{18}$F-BMS-986192 ($^{18}$Fluor-labelled anti-PD-L1 Adnectin) uptake on positron emission tomography (PET) has been shown to correlate with PD-L1 expression in NSCLC, as has $^{89}$Zirconium-nivolumab for PD-L1 expression, both in early phase clinical trials [13]. In both cases, inter- and intra-tumoural heterogeneity was demonstrated, consistent with the findings described in the early phase trial of $^{99m}$TcNM-01 SPECT/CT. An important characteristic of $^{99m}$TcNM-01 is that it is a small (14.3 kDa) antigen-binding fragment radiotracer with rapid blood clearance, with optimal SPECT/CT imaging performed at just 2 h following administration. As $^{99m}$TcNM-01 does not directly block the PD-L1 binding site, it does not interfere with the PD-1/PD-L1 axis and thus has the potential to assess whole-body PD-L1 status before, during and after anti-PD-L1 therapy. Whilst PET/CT provides a higher degree of spatial resolution, there are some notable benefits to SPECT/CT imaging. $^{99m}$Tc radioisotope and SPECT imaging are both more widely

### Table 2 Interobserver agreement

| SPECT        | Observer A | Observer B | Observer C | ICC (95% CI) | ICC level of agreement |
|--------------|------------|------------|------------|--------------|------------------------|
|              | ROI$\text{max}$ (mean ± SD) | ROI$\text{max}$ (mean ± SD) | ROI$\text{max}$ (mean ± SD) |              |                        |
| Malignant lesion(s) ROI |              |            |            |              |                        |
| Primary lung tumour (T) | 548 ± 150  | 560 ± 154  | 568 ± 157  | 0.94 (0.90–0.97) | Good to excellent       |
| Lymph node metastasis (LN) | 459 ± 167  | 461 ± 167  | 448 ± 163  | 0.97 (0.95–0.98) | Excellent               |
| Healthy reference tissue |              |            |            |              |                        |
| Blood pool (BP) | 260 ± 80   | 295 ± 80   | 270 ± 83   | 0.90 (0.84–0.94) | Good to excellent       |
| Lung (freehand) | 249 ± 146  | 310 ± 157  | 251 ± 88   | 0.84 (0.75–0.90) | Moderate to excellent    |
| Lung (AA) | 279 ± 113  | 279 ± 108  | 250 ± 94   | 0.89 (0.82–0.93) | Good to excellent        |
| Lung (C) | 307 ± 121  | 286 ± 129  | 288 ± 128  | 0.88 (0.81–0.95) | Excellent               |
| Liver (freehand) | 1121 ± 274 | 1262 ± 288 | 1194 ± 274 | 0.97 (0.95–0.99) | Excellent               |
| Liver (GOJ) | 1116 ± 264 | 1185 ± 270 | 1219 ± 283 | 0.95 (0.93–0.97) | Excellent               |

| Ratios | ROI$\text{max}$ ratio (mean ± SD) | ROI$\text{max}$ ratio (mean ± SD) | ROI$\text{max}$ ratio (mean ± SD) | ICC (95% CI) | ICC level of agreement |
|--------|---------------------------------|---------------------------------|---------------------------------|--------------|------------------------|
| T:BP   | 2.29 ± 0.98                     | 1.99 ± 0.67                     | 2.20 ± 0.77                     | 0.83 (0.73–0.90) | Moderate to good        |
| TL (freehand) | 2.56 ± 1.18                  | 2.01 ± 0.71                     | 2.40 ± 0.86                     | 0.79 (0.68–0.88) | Moderate to good        |
| TL (AA) | 2.10 ± 0.75                     | 2.17 ± 0.86                     | 2.41 ± 0.90                     | 0.85 (0.77–0.91) | Good to excellent       |
| TL (C) | 1.92 ± 0.71                     | 2.20 ± 0.92                     | 2.18 ± 0.93                     | 0.80 (0.69–0.88) | Moderate to good        |
| LN:BP | 1.86 ± 0.65                     | 1.65 ± 0.51                     | 1.70 ± 0.65                     | 0.87 (0.81–0.92) | Good to excellent       |

Malignant lesion and healthy tissue reference measurements (ROI$\text{max}$ mean ± SD) and their ratios of all three observers with intraclass correlation coefficient (ICC), their 95% confidence interval (CI) and descriptive ICC level of agreement

AA aortic arch, BP blood pool, C carina, CI confidence interval, ICC intraclass correlation coefficient, GOJ gastroesophageal junction, L lung, LN lymph node metastasis, ROI region of interest, T primary lung tumour
available and relatively inexpensive. Concerns regarding the non-standardised quantification techniques for SPECT/CT may not be fully justified if quantification techniques are reproducible and reliable. Applying simple rules to ROI\textsubscript{max} scoring may improve both inter- and intraobserver agreement, as demonstrated in this study where applying a set 3-cm sphere to score the unaffected lung at the level of the aortic arch improved the interobserver ICC. Whilst we did not show any significant improvement in agreement applying a similar rule to the liver, both inter- and intraobserver ICC remained excellent, suggesting that simple rule-based approaches may be used to standardise and simplify image interpretation without significant impact on quantification.

Fig. 2 Interobserver Bland-Altman level of agreement plots for \( \log_{10} T:BP \) (a–c) and \( \log_{10} LN:BP \) (d–f) scores. Upper and lower 95% limits of agreement represented by dashed lines. Solid horizontal lines represent between-observer mean difference. a T:BP scores observer A versus B \((\beta = 0.13, p = 0.117)\); b T:BP scores observer A versus C \((\beta = 0.07, p = 0.375)\); c T:BP scores observer B versus C \((\beta = -0.06, p = 0.410)\); d LN:BP scores observer A versus B \((\beta = 0.11, p = 0.047)\); e LN:BP scores observer A versus C \((\beta = -0.06, p = 0.448)\); f LN:BP scores observer B versus C \((\beta = -0.17, p = 0.020)\).
There are some limitations to this study. Firstly, it is limited by its sample size; nevertheless, the relatively narrow confidence intervals suggest a good estimate of the agreement. Despite good to excellent interobserver agreement, the mean sensitivity and specificity were relatively poor with some discrepant cases resulting in a PD-L1 assessment determined by T:BP of $[\text{Tc}]\text{NM-01}$ discordant with that found on IHC. This is not unexpected considering that heterogeneity of PD-L1 measured by IHC is widely reported in the literature and was demonstrated on $[\text{Tc}]\text{NM-01}$ assessment in our previous study [11]. In addition, the cut-off value of T:BP $\geq 2.32$ correlating with PD-L1 of $\geq 1\%$ on IHC was determined on a small sample size and requires further validation in larger cohorts [11]. It is also important to note that the patient cohort was relatively heterogenous with regards to tumour staging. Due to the low number of measurable extra-nodal (lung and bone) metastases in the cohort ($n=8$), statistical analysis using ICC of the quantitative assessment of $[\text{Tc}]\text{NM-01}$ in these lesions was not possible. With further understanding of the relationship between PD-L1 expression by IHC and $[\text{Tc}]\text{NM-01}$ SPECT/CT, it may be possible for both quantitative (as described in this study) and qualitative assessments to be made by observers blind to IHC PD-L1 expression, and their agreement evaluated. SPECT is a highly sensitive imaging modality but has relatively poor resolution; further optimisation with iterative reconstruction methods along with CT attenuation and scatter corrections have the potential to further improve and standardise quantification [14]. Novel SPECT reconstruction techniques that enable standardised quantification will be employed in forthcoming PECAn and PELICAN studies [EudraCT 2020-002809-26] to further investigate and validate $[\text{Tc}]\text{NM-01}$ SPECT/CT clinically. This would also enable quantitative comparison with other PD-L1 PET radionuclides, for example the aforementioned $18\text{F}$-BMS-986192 [13].

Table 3 Summary of PD-L1 assessments made by T:BP using $\geq 2.32$ as definition of positive result by $[\text{Tc}]\text{NM-01}$ SPECT/CT and $\geq 1\%$ by IHC, along with interobserver mean sensitivity and specificity

| Observer | T:BP $\geq 2.32$ and PD-L1 $\geq 1\%$ ($n$) | T:BP $< 2.32$ and PD-L1 $< 1\%$ ($n$) | T:BP $\geq 2.32$ and PD-L1 $< 1\%$ ($n$) | T:BP $< 2.32$ and PD-L1 $\geq 1\%$ ($n$) |
|----------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
| Observer A | 8                                           | 3                                           | 2                                           | 3                                           |
| Observer B | 5                                           | 4                                           | 1                                           | 6                                           |
| Observer C | 7                                           | 4                                           | 1                                           | 4                                           |
| Mean sensitivity | 61\%                                      |                                            |                                            |                                            |
| Mean specificity | 73\%                                     |                                            |                                            |                                            |

Table 4 Discrepant cases with individual observer and consensus 2-h T:BP scores (positive $\geq 2.32$). PD-L1 tumour proportion score (TPS) $\geq 1\%$ considered positive by immunohistochemistry (IHC)

| Patient no. | PD-L1 expression by IHC | TPS (%) | PD-L1 Assessment | Observer A | T:BP | PD-L1 Assessment | Observer B | T:BP | PD-L1 Assessment | Observer C | T:BP | PD-L1 Assessment | Consensus | T:BP | PD-L1 Assessment | Concordance with IHC |
|-------------|-------------------------|---------|------------------|-------------|------|------------------|-------------|------|------------------|-------------|------|------------------|------------|------|------------------|----------------------|
| 6           | $+$                      | 3       |                 | 1.39        | $-$  | 1.79            | $-$         | 2.18 | 2.32            | $-$         | 1.67 | $-$              | Discordant | 1.97 | $<$ 2.32         | Discordant            |
| 9           | $+$                      | 1       |                 | 1.93        | $+$  | 2.00            | $-$         | 1.97 | 2.32            | $-$         | 1.67 | $<$ 2.32         | Discordant | 1.97 | $<$ 2.32         | Discordant            |
| 11          | $+$                      | 2       |                 | 2.06        | $+$  | 2.37            | $+$         | 1.99 | 2.32            | $-$         | 2.00 | $<$ 2.32         | Discordant | 1.99 | $<$ 2.32         | Discordant            |
| 14          | $+$                      | 10      |                 | 1.74        | $-$  | 1.98            | $-$         | 1.57 | 2.32            | $-$         | 1.97 | $<$ 2.32         | Discordant | 1.99 | $<$ 2.32         | Discordant            |
| 16          | $+$                      | 2       |                 | 2.21        | $-$  | 2.47            | $+$         | 2.47 | 2.00            | $+$         | 2.47 | $+$              | Concordant | 2.47 | $+$              | Concordant            |
| 17          | $+$                      | 65      |                 | 2.29        | $-$  | 2.70            | $+$         | 3.00 | 2.32            | $+$         | 3.00 | $+$              | Concordant | 2.70 | $+$              | Concordant            |
| 20          | $-$                      | 0       |                 | 2.19        | $-$  | 3.56            | $-$         | 2.19 | 2.32            | $-$         | 2.19 | $<$ 2.32         | Concordant | 2.19 | $<$ 2.32         | Concordant            |
| 21          | $-$                      | 0       |                 | 3.41        | $+$  | 6.69            | $-$         | 4.27 | 2.32            | $+$         | 4.27 | $+$              | Discordant | 4.27 | $+$              | Discordant            |

Positive (+), negative (−)
Conclusion

Overall, good to excellent inter- and intraobserver agreement of the quantitative assessment of $[^{99m}\text{Tc}]$NM-01 SPECT/CT in NSCLC was demonstrated in this study. With correlation between PD-L1 expression determined by $[^{99m}\text{Tc}]$NM-01 SPECT/CT and by immunohistochemistry previously demonstrated, there is considerable potential for $[^{99m}\text{Tc}]$NM-01 SPECT/CT to reliably assess PD-L1 expression, with further analysis in subsequent clinical trials now being conducted.
Acknowledgements
The authors would like to thank all the participants and staff involved in this study. Additionally, the authors acknowledge colleagues at Shanghai General Hospital, China, King’s College London, Guy’s and St Thomas’ PET Centre and the Guy’s Comprehensive Cancer Centre, London, UK, for their contributions.

Authors’ contributions
DJH, GC, VG and GJRC were responsible for study concept and design, data analysis and interpretation, writing, reviewing and editing the manuscript. DJH, GC and GJRC were responsible for observer rating. DJH and GJRC made the final decision to approve and submit the final manuscript. All authors read and approved the final manuscript.

Funding
This research was supported by NanoMab Technology Limited. The authors acknowledge financial support from the Wellcome Trust EPSRC Centre for Medical Engineering at King’s College London (WT203148/Z/16/Z), and UK Research & Innovation London Medical Imaging and Artificial Intelligence Centre.

Availability of data and materials
The data sets used and analysed during the current study are available from the corresponding author on reasonable request.

Code availability
Not applicable.

Ethics approval and consent to participate
Institutional ethics approval for this study was obtained from Shanghai General Hospital Ethics Committee (2016KY220). Participants enrolled in the study provided written informed consent to participate.

Consent for publication
Not applicable.

Competing interests
DJH has received honoraria from Novartis and research funding from NanoMab Technology Limited. GC provides consultancy for NanoMab Technology Limited. VG has received research support from Siemens Healthcare. GJRC has received research support from NanoMab Technology Ltd., Theragnostics Ltd. and Serac Healthcare Ltd. and provides consultancy for GE Healthcare and NanoMab Technology Ltd.

Author details
1 Department of Cancer Imaging, School of Biomedical Engineering and Imaging Sciences, King’s College London, 4th Floor, Lambeth Wing, St Thomas’
References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.

2. Yuan M, Huang L-L, Chen J-H, Wu J, Xu Q. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Therapy. 2019;4(1):10. https://doi.org/10.1038/s41392-019-0099-9.

3. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Cásiz T, Fuluop A, et al. Updated Analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019;37(7):537–46. https://doi.org/10.1200/jco.18.00149.

4. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, Von Pawel J, et al. Atezolizumab versus docetaxel in previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2016;387(10027):1540–50. https://doi.org/10.1016/s0140-6736(16)00587-0.

5. Herbst RS, Baas P, Kim D-W, Felip E, Pérez-Grama JL, Han J-Y, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50. https://doi.org/10.1016/s0140-6736(15)01281-7.

6. McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekans M, Rehman J, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol. 2016;2(10):1393–400. https://doi.org/10.1001/jamaoncol.2015.3638.

7. Kim T-J, Hong SA, Kim O, Kim SJ, Yang J-H, Joung EK, et al. Changes in PD-L1 expression according to tumor infiltrating lymphocytes of acquired EGFR-TKI resistant EGFR-mutant non-small-cell lung cancer. Oncotarget. 2017. https://doi.org/10.18632/oncotarget.13475.

8. Udall M, Ruzzo M, Kenny J, Doherty J, Dahlin S, Robbins P, et al. PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics. Diagn Pathol. 2018. https://doi.org/10.1186/s13000-018-0689-9.

9. Xing Y, Chaud G, Liu C, Cool K, Dickson J, O’Donnell J, Zhao L, et al. Early phase I study of a 99mTc-Labeled single-domain antibody in SPECT/CT assessment of PD-L1 expression in non-small-cell lung cancer. J Nucl Med. 2019;60(9):1213–20. https://doi.org/10.2967/jnume.118.224170.

10. Koo TK, Li MY. Quantitative SPECT: the time is now. EJNMMI Res. 2016;6:145. https://doi.org/10.1007/s41504-016-0092-2.

11. Nienaber CA, Zhang Q, Heussler H, Huisman MC, Bahce I, Hoekstra OS, Van Dongen HC. Imaging of PD-L1 expression in non-small cell lung cancer. J Nucl Med. 2019;60(9):1213–20. https://doi.org/10.2967/jnume.118.224170.

12. Udall M, Ruzzo M, Kenny J, Doherty J, Dahlin S, Robbins P, et al. PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics. Diagn Pathol. 2018. https://doi.org/10.1186/s13000-018-0689-9.

13. Xing Y, Chaud G, Liu C, Cool K, Dickson J, O’Donnell J, Zhao L, et al. Early phase I study of a 99mTc-Labeled single-domain antibody in SPECT/CT assessment of PD-L1 expression in non-small-cell lung cancer. J Nucl Med. 2019;60(9):1213–20. https://doi.org/10.2967/jnume.118.224170.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.